VXRT

On the surface VXRT looks like a cheap turnaround: FY2025 revenue jumped +726.7% to $237M, it swung to $16.3M net income (first profit after years of deep losses), P/E is 9.1 and P/S 0.6. But the filing makes clear this is a mirage. Vaxart describes itself as a 'clinical-stage biotechnology company' with no approved, commercially selling product — its norovirus, COVID/SARS-CoV-2, flu and HPV candidates are all still in development. The revenue that created 2025's profit is government funding: the ATI-RRPV COVID contract (up to $460.7M) plus BARDA, which is cost-plus reimbursement of R&D, not product sales. This is why R&D expense ($202M, +171.6%) and revenue ($237M) move together and operating margin is a thin 7.6% — the government is essentially paying the lab bill and a small fee on top. That is neither high-quality nor recurring.

The durability problem is spelled out in the MD&A itself: BARDA (2024 ASPR-BARDA) revenue collapsed from $8.7M in 2024 to just $0.6M in 2025 as milestones ran off. The remaining engine (RRPV) is a specific, terminable COVID program subject to shifting federal vaccine priorities and HHS budget politics — a single-customer, single-program dependency. There is also 'non-cash royalty revenue' that is simply remitted straight to HCRP (the Inavir royalty buyer, $4.4M cumulative shortfall), so it flatters the top line without adding cash. Strip the contract, and you are left with a pre-revenue biotech burning R&D against $53.8M cash and only $7.71M of operating cash flow.